Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Duchenne-Muscular-Dystrophy"

13 News Found

Roche to present data across neuroscience portfolio at 2022 AAN Annual Meeting
News | March 25, 2022

Roche to present data across neuroscience portfolio at 2022 AAN Annual Meeting

Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment

Emmes acquires Casimir, its fourth major acquisition
Biotech | March 11, 2022

Emmes acquires Casimir, its fourth major acquisition

Casimir further differentiates Emmes’ industry-leading rare disease research capabilities

India extends concession on life-saving Covid-19 drugs till December 2021
News | September 18, 2021

India extends concession on life-saving Covid-19 drugs till December 2021

The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines

Latest Stories

Datroway delivers first-ever overall survival breakthrough in 1st-line metastatic triple-negative breast cancer without immunotherapy

Pharmanovia appoints Stephan Eder as CEO

Alembic and Amlan launch feed additive solutions for poultry

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging